There are currently 99 clinical trials in Amarillo, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Harrington Cancer Center, The Don and Sybil Harrington Cancer Center, Texas Tech University Health Science Center-Amarillo and Texas Tech University Health Sciences Center School of Medicine. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
Recruiting
This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course chemoradiation in patients with stage II-III rectal cancer. Combination chemotherapy drugs, such as FOLFIRINOX (fluorouracil, irinotecan, leucovorin, and oxaliplatin), FOLFOX (leucovorin, fluorouracil, oxaliplatin, and irinotecan ), and CAPOX (capecitabin and oxaliplatin) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/19/2024
Locations: The Don and Sybil Harrington Cancer Center, Amarillo, Texas
Conditions: Locally Advanced Rectal Carcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
Recruiting
The purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment. Participants who achieve complete clinical response (cCR) following dostarlimab treatment will undergo non-operative management (NOM), including close surveillance for recurrent disease. The goal of the study is to determine if Dostarlimab therapy alone is an effective... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/18/2024
Locations: GSK Investigational Site, Amarillo, Texas
Conditions: Neoplasms, Rectal
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
Recruiting
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may... Read More
Gender:
All
Ages:
45 years and above
Trial Updated:
02/15/2024
Locations: Research Site, Amarillo, Texas
Conditions: Acute Coronary Syndrome
Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma
Recruiting
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after treatment and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: Texas Oncology - Amarillo, Amarillo, Texas
Conditions: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)
Recruiting
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care.
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
02/13/2024
Locations: Research Site, Amarillo, Texas
Conditions: Asthma
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
Recruiting
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medic... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/11/2024
Locations: Amarillo Med Spec LLP, Amarillo, Texas
Conditions: Obesity
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
Recruiting
The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability of dexpramipexole in participants with eosinophilic asthma.
Gender:
All
Ages:
Between 12 years and 99 years
Trial Updated:
02/09/2024
Locations: Research Site 40001-068, Amarillo, Texas
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
Recruiting
This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.
Gender:
All
Ages:
Between 12 years and 99 years
Trial Updated:
02/09/2024
Locations: Research Site 20001-068, Amarillo, Texas
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
Recruiting
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may in... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: The Don and Sybil Harrington Cancer Center, Amarillo, Texas
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)
Recruiting
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
02/01/2024
Locations: Research Site, Amarillo, Texas
Conditions: Asthma
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
Recruiting
The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: Clinical Trial Site, Amarillo, Texas
Conditions: Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Recruiting
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whethe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Texas Oncology PA - Amarillo, Amarillo, Texas
Conditions: Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma